Term
|
Definition
| accumulation in food vacuole, blocks heme poly 2. first choice antimalarial for ovm, and cq- sensitive f, can be profylaxis, eryhtrocytic forms, EFFEECTive againts gametocytes other than falciparum 3.well abrosbed GI and IM 4.safe, when dosed too rapidly may cause cardio, cns , GI effects, aslo hemolysis in G6PD dficiency |
|
|
Term
|
Definition
| cq=restistant for mild attacks, can be used for profvx |
|
|
Term
|
Definition
| use with oral quinine for cq resistance for mild attacks instead of malarone. If attack is svere, use iv quinine, doxy can be used for prof |
|
|
Term
|
Definition
| MOA-UNK 2.can be used for prof, has falciparum activity and vivax actviity 3. taken orally, absorp aided by food 4.conntraindicated for patients w cardio conduction abnormalities. Teratogenic at high doses. |
|
|
Term
|
Definition
| samemoa as cq, but more toxic and less effewctive 2. firstlinine treatment w antifolates for cq-resistnace, erythrocytic forms, EFFEECTive againts gametocytes other than falciparum 3.cinchonism-tinnitus, visual distrub, geadache; hem disturbances, hypoglycemia hypotension, EKG abnorm, muscle effects |
|
|
Term
|
Definition
| MOA-UNK 2.only one to eliminatnte latent shizonts, not effective for erythrocytic, gametocidal fo rall maralri parasites. 3. GI wel labsorbed 44. G6PD deficiens, methoglobiniema, and hemolytic anemia. Oterwise no problmes with normal dose, may cause GI stress |
|
|
Term
| antifolates:fansidar: fuladoxine and pryimetamine |
|
Definition
| MOA-synergtic effect. Pryimetamine- DHFR inhibitor, Sulfa- Dihydropetrate synthase 2.profylaxis 3. hi toxicity ofsulfa. Severse cutaneous reactions (steven johnson), anemia, contraindicated for pregnant or breast feeding women, or infants |
|
|
Term
|
Definition
| dstrutpin of mic membrane ptoential , itneferance with atp synth, synergistic with proguanil |
|
|
Term
|
Definition
| DHFR inhibtor, synergy of mitock membrane depol by atovaquone 2.resistance emerges rapidly 3. orally, activation by metabolism to cycloguanil,sosloweronset ofaction. 4.p450 metabolism, GI disturbances, contraidnicated in patients with severe renal |
|
|
Term
|
Definition
| MOA: prodrug- activation of nitro group via sensitive organism, this reduction is resposnbiel forantimicrobial activity. 2.wide variety of anaerobic parasites and bactreia. Kills trophs but not cysts of E hisolitical ,can erdaicdate both intestinal and extraintestinal infections. Clinical use: amebiasis, trichmoniasis. |
|
|
Term
|
Definition
| lumianl amebicide. MOA-UNK 2.not effective agaisnt trophs I nintestianlwal lor extraintestinal tissues, effective only in bowel lumen. 3.GI effects |
|
|
Term
|
Definition
| lumianl amebicide. MOA-UNK |
|
|
Term
|
Definition
| amingolucoside antibiotic, used as luminal amebicide 2. renal tox |
|
|
Term
|
Definition
| punoemicystis carini, pentamidine may also be used but higher tox. 2. punoemicystis carini, pentamidine may also be used but higher tox. |
|
|
Term
|
Definition
| treatment of toxoplasmosis, use wit sulfadizine and folinic acid |
|
|
Term
|
Definition
| 1.first lyne therapy for early typanosmiasis 2.side effects, GI; and some seizures, and even death |
|
|
Term
|
Definition
| alternativee. To first line trypansome |
|
|
Term
|
Definition
| prodrug 2.very nonspecific so lethal to host tissues 3.first line therapy for advanced disease of trypanosoma. 4.very toxic cns effects |
|
|
Term
|
Definition
| inhbits ornithine decarbox- first step in polyamien biosynt. 2nd line terapy for advanced disease of trapyanosome 4. blood cell effects (thrombocytopenia, lucopenia anemia) |
|
|
Term
|
Definition
| tryponasome treatment, eliminates detectable parastsised but not fully effective at their removal |
|
|
Term
| antimoney treatment (stibogluconate or antimonate) |
|
Definition
| interferes with redox 2. treats leishmaniasis 3. pacnreatitis, liver damage bone marrow suppresion muscle and joint pain |
|
|
Term
|
Definition
| drug of choice for resistance of leishmania to antimoney |
|
|
